阿柏西普
医学
血管抑制剂
贝伐单抗
眼科
黄斑变性
视力
视网膜
外科
化疗
作者
Mariana Rossi Thorell,Renata Portella Nunes,Gene W. Chen,Rishi R. Doshi,Jyoti Dugar,Mathew K. George,Brian T. Kim,Matthew D. Lowrance,Dimple Modi,Zayna Nahas,Giovanni Gregori,Zohar Yehoshua,William J. Feuer,Philip J. Rosenfeld
标识
DOI:10.3928/23258160-20141118-07
摘要
BACKGROUND AND OBJECTIVE: To evaluate the effects of switching to aflibercept in eyes with neovascular age-related macular degeneration (AMD) requiring frequent re-treatment with bevacizumab or ranibizumab. PATIENTS AND METHODS: Retrospective review of 73 eyes of 65 patients with neovascular AMD switched to aflibercept due to persistent or recurrent macular fluid after at least 1 year of intravitreal bevacizumab or ranibizumab with re-treatment at least every 6 weeks. Minimum post-switch follow-up was 6 months. All patients were treated using a treat-and-extend strategy. The treatment intervals immediately after and before the switch were the same. RESULTS: The mean pre-switch anti-VEGF therapy duration was 45 months, and the mean number of injections was 31. In the 6 months after the switch, the average number of injections was reduced by 0.6 compared with the 6 months before the switch (P < .001). Visual acuity was unchanged during this period (P = .78). Central retinal thickness (CRT) decreased by 19 µm after the switch (P < .001). Seventy eyes had vascularized retinal pigment epithelial detachments (PEDs). The decrease in the PED cube-root volume during the 6 months after the switch was statistically significant (-0.07 mm; P = .007). CONCLUSION: The number of injections, CRT, and PED volume decreased significantly after the switch to aflibercept, but visual acuity was unchanged.
科研通智能强力驱动
Strongly Powered by AbleSci AI